跳到正文
原文
The Lancet Psychiatry· Alejandro G Szmulewicz, Yu-Hsin Liang, Gonzalo Martínez-Alés, Ryan O’Dea, Lorna E Thorpe, Sarah Conderino, José M Rubio, Kerry Smith, Deepak K Sarpal, Covadonga M Díaz-Caneja, Celso Arango, Paul A Vöhringer, Sophia A Aldunate, Ridha Joober, Jai L Shah, Ashok Malla, Diane Fredrikson, Lakshmi N Yatham, Miguel A Hernán, Dost Öngür, BD-CAUSAL Collaboration·· 2026-10-01AI 评分36

心境稳定剂单药或联合治疗 vs 第二代抗精神病药单药治疗首发精神病性躁狂后续与维持疗效的靶试验模拟研究:来自 BD-CAUSAL 协作组在北美、智利和西班牙的数据

[Articles] Comparative effectiveness of mood stabiliser monotherapy versus second-generation antipsychotic monotherapy versus combination therapy for continuation and maintenance treatment after a first episode of psychotic mania in North America, Chile, and Spain: a target trial emulation using data from the BD-CAUSAL Collaboration

AI 导读

基于北美、智利和西班牙数据的靶试验模拟显示,在首发精神病性躁狂发作后的延续与维持治疗中,心境稳定剂单药或联合治疗组的复发风险低于第二代抗精神病药单药治疗组。研究结果支持在早期治疗中优先考虑使用心境稳定剂,但需要随机对照试验进一步确认。

来源:The Lancet Psychiatry · thelancet.com